Aurinia Pharmaceuticals (AUPH) Posts Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) posted its earnings results on Thursday. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), Morningstar.com reports. Aurinia Pharmaceuticals had a negative return on equity of 30.34% and a negative net margin of 12,536.05%. The firm had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.07 million.

Shares of AUPH traded up $0.05 during mid-day trading on Friday, reaching $5.65. The company had a trading volume of 883,496 shares, compared to its average volume of 444,432. Aurinia Pharmaceuticals has a 52 week low of $4.41 and a 52 week high of $6.69. The stock has a market cap of $476.10 million, a P/E ratio of -6.14 and a beta of 2.22.

A number of research firms have weighed in on AUPH. ValuEngine upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. HC Wainwright boosted their price target on Aurinia Pharmaceuticals to $15.00 and gave the stock a “buy” rating in a research report on Monday, August 13th. BidaskClub cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 8th. Cantor Fitzgerald set a $18.00 price target on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, August 11th. Finally, Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. Aurinia Pharmaceuticals currently has an average rating of “Buy” and an average target price of $11.79.

Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC boosted its position in shares of Aurinia Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock worth $31,082,000 after purchasing an additional 95,650 shares in the last quarter. BlackRock Inc. boosted its position in shares of Aurinia Pharmaceuticals by 45.2% in the 1st quarter. BlackRock Inc. now owns 1,045,121 shares of the biotechnology company’s stock worth $5,424,000 after purchasing an additional 325,408 shares in the last quarter. Ironwood Investment Management LLC boosted its position in shares of Aurinia Pharmaceuticals by 18.0% in the 2nd quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock worth $1,231,000 after purchasing an additional 33,279 shares in the last quarter. Creative Planning boosted its position in shares of Aurinia Pharmaceuticals by 8.2% in the 2nd quarter. Creative Planning now owns 171,200 shares of the biotechnology company’s stock worth $964,000 after purchasing an additional 13,000 shares in the last quarter. Finally, Stanley Laman Group Ltd. bought a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter worth approximately $276,000. 24.87% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/11/10/aurinia-pharmaceuticals-auph-posts-earnings-results.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Read More: Diversification For Individual Investors

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply